• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

致病性Th17细胞对Graves眼病眼眶纤维化和脂肪生成的调控

Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy.

作者信息

Fang Sijie, Huang Yazhuo, Zhong Sisi, Li Yangyang, Zhang Yidan, Li Yinwei, Sun Jing, Liu Xingtong, Wang Yang, Zhang Shuo, Xu Tianle, Sun Xiaodong, Gu Ping, Li Dan, Zhou Huifang, Li Bin, Fan Xianqun

机构信息

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China.

Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.

出版信息

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4273-4283. doi: 10.1210/jc.2017-01349.

DOI:10.1210/jc.2017-01349
PMID:28938397
Abstract

CONTEXT

T helper (Th)17 cells are correlated with many human autoimmune disorders, including Graves disease, and may play key roles in the pathogenesis of Graves orbitopathy (GO).

OBJECTIVE

To study the phenotype of Th17 cells in patients with GO and healthy subjects, investigate the fibrosis and adipogenesis in orbital fibroblasts (OFs) modulated by interleukin (IL)-17A, and determine the interaction between Th17 cells and OFs.

DESIGN/SETTING/PARTICIPANTS: Blood samples and orbital tissues from GO patients and healthy controls were collected.

MAIN OUTCOME MEASURES

We conducted multicolor flow cytometry, immunohistochemical and immunofluorescent stainings, Western blotting, a PathScan intracellular signaling assay, Luminex and enzyme-linked immunosorbent assays, and protein mass spectrum.

RESULTS

Interferon-γ- and IL-22-expressing Th17 cells are increased in GO patients, which are positively related to clinical activity score. Costimulatory molecules are highly expressed in GO orbits and most GO OFs are CD90+. IL-17A promotes TGF-β-induced fibrosis in CD90+ OFs but impedes 15-deoxy-Δ12,14-prostaglandin J2-induced adipogenesis in CD90- OFs. Th17 cells promote proinflammatory cytokine secretion in both CD90+ and CD90- OFs. Meanwhile, both CD90+ and CD90- OFs contribute to Th17 cell differentiation through prostaglandin E2 production, which can be attenuated by indomethacin. Furthermore, Th17 cells upregulate costimulatory molecule expression on OFs.

CONCLUSION

Our findings unravel the pathogenicity of IL-17A in the initiation and progression of GO. In-depth interpretation of the molecular basis of OFs delineated by CD90 and Th17-OF interaction will help to afford a novel approach to better therapeutic strategies for GO.

摘要

背景

辅助性T细胞17(Th17)与包括格雷夫斯病在内的多种人类自身免疫性疾病相关,可能在格雷夫斯眼眶病(GO)的发病机制中起关键作用。

目的

研究GO患者和健康受试者中Th17细胞的表型,探讨白细胞介素(IL)-17A调节眼眶成纤维细胞(OFs)的纤维化和脂肪生成情况,并确定Th17细胞与OFs之间的相互作用。

设计/地点/参与者:收集GO患者和健康对照者的血液样本和眼眶组织。

主要观察指标

我们进行了多色流式细胞术、免疫组织化学和免疫荧光染色、蛋白质印迹法、PathScan细胞内信号检测、Luminex和酶联免疫吸附测定以及蛋白质质谱分析。

结果

GO患者中表达干扰素-γ和IL-22的Th17细胞增加,这与临床活动评分呈正相关。共刺激分子在GO眼眶中高表达,大多数GO OFs为CD90+。IL-17A促进CD90+ OFs中转化生长因子-β诱导的纤维化,但抑制CD90- OFs中15-脱氧-Δ12,14-前列腺素J2诱导的脂肪生成。Th17细胞促进CD90+和CD90- OFs中促炎细胞因子的分泌。同时,CD90+和CD90- OFs均通过前列腺素E2的产生促进Th17细胞分化,吲哚美辛可减弱这种作用。此外,Th17细胞上调OFs上共刺激分子的表达。

结论

我们的研究结果揭示了IL-17A在GO发生和发展中的致病性。深入解读由CD90和Th17-OF相互作用所描绘的OFs分子基础,将有助于为GO提供更好治疗策略的新方法。

相似文献

1
Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy.致病性Th17细胞对Graves眼病眼眶纤维化和脂肪生成的调控
J Clin Endocrinol Metab. 2017 Nov 1;102(11):4273-4283. doi: 10.1210/jc.2017-01349.
2
Immunophenotype of Lacrimal Glands in Graves Orbitopathy: Implications for the Pathogenesis of Th1 and Th17 Immunity.格雷夫斯眼眶病中泪腺的免疫表型:对Th1和Th17免疫发病机制的启示
Thyroid. 2022 Aug;32(8):949-961. doi: 10.1089/thy.2021.0671. Epub 2022 Jun 24.
3
Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.氯喹和羟氯喹通过靶向眼眶成纤维细胞在格雷夫斯眼眶病治疗中的新作用
J Clin Endocrinol Metab. 2020 Jun 1;105(6):1906-17. doi: 10.1210/clinem/dgaa161.
4
Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an Model of Graves' Orbitopathy.双硫仑在格雷夫斯眼眶病模型中发挥抗脂肪生成、抗炎和抗纤维化治疗作用。
Thyroid. 2022 Mar;32(3):294-305. doi: 10.1089/thy.2021.0246. Epub 2021 Dec 31.
5
Insights Into Local Orbital Immunity: Evidence for the Involvement of the Th17 Cell Pathway in Thyroid-Associated Ophthalmopathy.局部眼眶免疫的新认识:Th17 细胞通路在甲状腺相关性眼病中的作用。
J Clin Endocrinol Metab. 2019 May 1;104(5):1697-1711. doi: 10.1210/jc.2018-01626.
6
IL-17A Exacerbates Fibrosis by Promoting the Proinflammatory and Profibrotic Function of Orbital Fibroblasts in TAO.白细胞介素-17A通过促进甲状腺相关眼病中眼眶成纤维细胞的促炎和促纤维化功能加重纤维化。
J Clin Endocrinol Metab. 2016 Aug;101(8):2955-65. doi: 10.1210/jc.2016-1882. Epub 2016 May 25.
7
Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.雌性格雷夫斯眼眶病小鼠模型眼眶成纤维细胞中脂肪生成和透明质酸的致病表型
Endocrinology. 2016 Oct;157(10):3771-3778. doi: 10.1210/en.2016-1304. Epub 2016 Aug 23.
8
CD40 Enhances Sphingolipids in Orbital Fibroblasts: Potential Role of Sphingosine-1-Phosphate in Inflammatory T-Cell Migration in Graves' Orbitopathy.CD40 增强眼眶成纤维细胞中的神经鞘脂:鞘氨醇-1-磷酸在格雷夫斯眼病炎症性 T 细胞迁移中的潜在作用。
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5391-5397. doi: 10.1167/iovs.18-25466.
9
Characterisation of human orbital fibroblasts cultivated from intraconal, nasal and central adipose tissues.从眶内、鼻腔和中央脂肪组织培养的人眼眶成纤维细胞的特征。
Br J Ophthalmol. 2021 Feb;105(2):290-296. doi: 10.1136/bjophthalmol-2018-313699. Epub 2019 Sep 5.
10
M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.M1 样巨噬细胞调节格雷夫斯眼病眼眶成纤维细胞的纤维化和炎症:可溶性白细胞介素 6 受体的潜在相关性。
Thyroid. 2023 Mar;33(3):338-350. doi: 10.1089/thy.2022.0254. Epub 2023 Feb 20.

引用本文的文献

1
Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions.格雷夫斯眼病的新兴治疗方法:药物干预的最新进展
Front Immunol. 2025 Jul 25;16:1647602. doi: 10.3389/fimmu.2025.1647602. eCollection 2025.
2
Machine learning unveils hypoxia-immune gene hub for clinical stratification of thyroid-associated ophthalmopathy.机器学习揭示用于甲状腺相关性眼病临床分层的缺氧免疫基因枢纽。
Sci Rep. 2025 Jul 1;15(1):22021. doi: 10.1038/s41598-025-05107-9.
3
Single-cell multiomic analysis unveils the immune landscape dynamics of graves' ophthalmopathy.
单细胞多组学分析揭示了格雷夫斯眼病的免疫格局动态变化。
Commun Biol. 2025 May 12;8(1):732. doi: 10.1038/s42003-025-08115-7.
4
The role of IL-6 in thyroid eye disease: an update on emerging treatments.白细胞介素-6在甲状腺眼病中的作用:新兴治疗方法的最新进展
Front Ophthalmol (Lausanne). 2025 Apr 14;5:1544436. doi: 10.3389/fopht.2025.1544436. eCollection 2025.
5
Targeted immunotherapies for Graves' thyroidal & orbital diseases.针对格雷夫斯甲状腺及眼眶疾病的靶向免疫疗法。
Front Immunol. 2025 Mar 12;16:1571427. doi: 10.3389/fimmu.2025.1571427. eCollection 2025.
6
Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.甲状腺相关性眼病药物治疗的新观点
Front Endocrinol (Lausanne). 2025 Jan 13;15:1469268. doi: 10.3389/fendo.2024.1469268. eCollection 2024.
7
A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.甲状腺眼病发病机制的全面综述:从免疫失调到新的诊断和治疗方法。
Int J Mol Sci. 2024 Oct 29;25(21):11628. doi: 10.3390/ijms252111628.
8
A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy.一种结合转录组学和蛋白质组学的方法揭示了S100A4作为Graves眼病的潜在生物标志物。
Front Genet. 2024 Sep 18;15:1342205. doi: 10.3389/fgene.2024.1342205. eCollection 2024.
9
IL-17 and IL-38 gene polymorphisms in thyroid-associated ophthalmopathy.白细胞介素-17 和白细胞介素-38 基因多态性与甲状腺相关眼病的关系。
Int Ophthalmol. 2024 Sep 18;44(1):379. doi: 10.1007/s10792-024-03317-0.
10
Graves disease: latest understanding of pathogenesis and treatment options.格雷夫斯病:发病机制和治疗选择的最新认识。
Nat Rev Endocrinol. 2024 Nov;20(11):647-660. doi: 10.1038/s41574-024-01016-5. Epub 2024 Jul 22.